Relay Therapeutics, INC 8-K filings

Relay Therapeutics announced an amendment to its common stock sales agreement, increasing the at-the-market offering program to $462.98 million and reported its second quarter 2026 financial results, including a net loss of $83.7 million.

Relay Therapeutics stockholders approved an increase in authorized common stock from 300 million to 450 million shares at the 2026 Annual Meeting.

Relay Therapeutics has priced an underwritten public offering of common stock to raise approximately $296.8 million in net proceeds.

Relay Therapeutics announced initial Phase 2 ReInspire trial data for zovegalisib in vascular anomalies, showing a 60% volumetric response rate and strong patient-reported outcomes, with a favorable safety profile for chronic use.

Relay Therapeutics reported Q1 2026 financial results, highlighting progress in its zovegalisib program for breast cancer and vascular anomalies, and initiated a Phase 1/2 trial for RLY-8161.

Relay Therapeutics announced positive clinical data for its zovegalisib triplet combination, supporting advancement to Phase 3 development for frontline metastatic breast cancer.

Relay Therapeutics announced positive Phase 1/2 ReDiscover trial data for zovegalisib in PI3K-mutated metastatic breast cancer, supporting its Phase 3 advancement.

Relay Therapeutics announced improved 2025 financial results, extended cash runway into 2029, and outlined critical clinical data readouts for its zovegalisib program in 2026.

Relay Therapeutics announced that its drug candidate, zovegalisib, received Breakthrough Therapy designation from the FDA for advanced breast cancer.

Relay Therapeutics announced its third quarter 2025 financial results, reporting a reduced net loss and strong cash position, alongside the appointment of two experienced biotech CEOs to its Board of Directors.

Relay Therapeutics reported second quarter 2025 financial results, highlighted by the initiation of its Phase 3 ReDiscover-2 trial and consistent RLY-2608 clinical data.

Relay Therapeutics, a clinical-stage precision medicine company, announced the appointment of Claire Mazumdar, Ph.D., MBA, to its Board of Directors and as Chair of the Audit Committee, following the resignation of Jami Ruben.

Relay Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where shareholders re-elected two Class II directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as its independent auditor.

Relay Therapeutics, Inc. has announced a significant real estate restructuring, terminating its Binney Street lease early and entering a new Kendall Square lease, projected to save approximately $16 million in rent expenses.

Relay Therapeutics announced its Q1 2025 financial results, highlighting a cash runway extended into 2029 and progress in its clinical programs.

Relay Therapeutics reports promising progress in its RLY-2608 breast cancer program and a strong cash position to fund a pivotal Phase 3 trial.

Relay Therapeutics is advancing its pipeline with a focus on RLY-2608 in breast cancer and expanding into vascular malformations, Fabry disease, and NRAS-driven solid tumors, supported by a strong cash position.

Relay Therapeutics reports promising interim clinical data for RLY-2608, showing a median progression-free survival of 11.4 months in second-line breast cancer patients.

Relay Therapeutics reported encouraging interim data for RLY-2608 in breast cancer and a strong cash position, while also streamlining operations.

Relay Therapeutics has launched a public offering of 28,571,429 shares of its common stock at $7.00 per share, aiming to raise approximately $200 million.

Relay Therapeutics reported positive interim clinical data for RLY-2608, showing a 9.2-month median progression-free survival in heavily pre-treated patients with PI3K-mutated, HR+/HER2metastatic breast cancer.

Relay Therapeutics reported its second quarter 2024 financial results, highlighted by progress in clinical programs and the announcement of new pre-clinical programs.

Relay Therapeutics has received notice from Genentech to terminate their collaboration agreement for the development of RLY-1971, effective in 180 days.

Relay Therapeutics has announced a clinical trial collaboration with Pfizer to evaluate a combination therapy for breast cancer and has also unveiled three new programs from its pre-clinical pipeline.

Relay Therapeutics held its 2024 Annual Meeting of Stockholders, where directors were elected, executive compensation was approved in an advisory vote, and the company's independent auditor was ratified.

Relay Therapeutics announced its first quarter 2024 financial results, highlighting a strong cash position and progress in its clinical programs.

Relay Therapeutics announced its fourth quarter and full year 2023 financial results, highlighting progress in clinical programs and a strong cash position to fund operations into the second half of 2026.